4-Methyl-piperazin-1-carbonsaeure-isopentylester | 18722-23-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-Methyl-piperazin-1-carbonsaeure-isopentylester
• 英文别名: 1-Piperazinecarboxylic acid, 4-methyl-, 3-methylbutyl ester；3-methylbutyl 4-methylpiperazine-1-carboxylate
• CAS: 18722-23-1
• 化学式: C₁₁H₂₂N₂O₂
• 分子量: 214.308
• InChiKey: XPXQBEZMCCMMHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE
  申请人：BIOWAY., INC

  公开号：US20200157048A1

  公开（公告）日：2020-05-21

  The present application relates to a novel pentadienoyl compound and a pharmaceutical composition including the same. The pentadienoyl compound of the present application may be used to prevent or treat fatty liver and fatty liver-related disease by inhibiting lipogenesis and lipid accumulation in cells and activating lipid metabolism. In addition, the pentadienoyl compound of the present application may increase a SIRT1 expression level in cells or SIRT1 activity, and thus may be used to prevent or treat a SIRT1-mediated disease. In addition, the pentadienoyl compound of the present application may reduce a CK2 expression level in cells or CK2 activity, and thus may be used to prevent or treat a CK2-mediated disease.

  本申请涉及一种新型的戊二烯酰化合物和包括该化合物的药物组合物。本申请的戊二烯酰化合物可用于通过抑制细胞内脂肪生成和脂质积累，激活脂质代谢，预防或治疗脂肪肝和脂肪肝相关疾病。此外，本申请的戊二烯酰化合物可能增加细胞中SIRT1的表达水平或SIRT1的活性，因此可用于预防或治疗SIRT1介导的疾病。此外，本申请的戊二烯酰化合物可能降低细胞中CK2的表达水平或CK2的活性，因此可用于预防或治疗CK2介导的疾病。
• NOVEL CYCLOSPORIN ANALOGUES
  申请人：Long Jiang

  公开号：US20110008285A1

  公开（公告）日：2011-01-13

  The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.
• NOVEL PROLINE SUBSTITUTED CYCLOSPORIN ANALOGUES
  申请人：Wang Guoqiang

  公开号：US20110008286A1

  公开（公告）日：2011-01-13

  The present invention provides novel proline substituted cyclosporinanalogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.
• US8349312B2
  申请人：——

  公开号：US8349312B2

  公开（公告）日：2013-01-08
• US8367053B2
  申请人：——

  公开号：US8367053B2

  公开（公告）日：2013-02-05